In Q1 2025, Acadia Healthcare reported $770.5 million in revenue and $8.4 million in net income. Adjusted EPS reached $0.40 and Adjusted EBITDA came in at $134.2 million, including $5 million in one-time costs related to a facility closure. The company added 378 new beds and repurchased $47.3 million in stock.

Acadia Healthcare's Q4 2024 revenue increased by 4.2% year-over-year to $774.2 million, driven by higher patient volumes and growth in same-facility revenue. However, net income declined to $32.6 million, impacted by increased operating expenses and facility-related costs. Adjusted EPS came in at $0.64, while adjusted EBITDA totaled $153.1 million, reflecting a $14.3 million professional liability reserve adjustment and a $5.0 million impact from facility closures.

Acadia Healthcare reported an 8.7% increase in revenue, totaling $815.6 million for Q3 2024. Net income attributable to Acadia was $68.1 million, or $0.74 per diluted share, while adjusted income was $84.1 million, or $0.91 per diluted share. The company is on track to expand its facilities and bed capacity.

Acadia Healthcare reported an 8.8% increase in revenue to $796.0 million and net income attributable to Acadia of $78.5 million, or $0.85 per diluted share, for the second quarter of 2024. The company continues to execute its growth strategy, adding beds to existing facilities and opening a new facility in Mesa, Arizona.

Acadia Healthcare reported a strong first quarter in 2024, with a 9.1% increase in revenue to $768.1 million. The company saw a 9.2% increase in same facility revenue, driven by a 6.9% increase in revenue per patient day and a 2.2% increase in patient days. Net income attributable to Acadia was $76.4 million, or $0.83 per diluted share, and adjusted EBITDA increased by 14.9% to $173.9 million.

Acadia Healthcare's Q4 2023 performance showcased strong revenue growth of 10.0% year-over-year, driven by a 10.3% increase in same-facility revenue. The company continued its growth strategy through facility expansions, de novo facilities, and joint ventures. Acadia provided full year and first quarter 2024 guidance, reflecting confidence in continued growth and profitability.

Acadia Healthcare reported a revenue of $750.3 million, a 12.5% increase year-over-year, and a net loss of $217.7 million, which included a $394.2 million legal settlement expense. Adjusted income was $83.9 million, with adjusted EBITDA at $175.9 million, reflecting strong operational execution and growth strategy.

Acadia Healthcare reported a revenue of $731.3 million, a 12.2% increase year-over-year. Net income attributable to Acadia was $72.3 million, or $0.79 per diluted share, and adjusted income from continuing operations was $84.7 million, or $0.92 per diluted share. The company also raised its full-year financial guidance.

Acadia Healthcare reported a strong start to 2023 with a 14.2% increase in revenue, reaching $704.3 million. The company's net income attributable to Acadia was $66.0 million, or $0.72 per diluted share, and adjusted income from continuing operations was $68.7 million, or $0.75 per diluted share. Acadia is on track with its growth strategy, including facility expansions and new facility developments.

Acadia Healthcare reported a revenue of $675.3 million for Q4 2022, a 13.8% increase compared to Q4 2021. Net income attributable to Acadia was $61.1 million, or $0.67 per diluted share, while adjusted income from continuing operations was $68.1 million, or $0.74 per diluted share.

Acadia Healthcare reported a revenue increase of 13.5% to $666.7 million, with same-facility revenue growth of 10.2%. Net income attributable to Acadia totaled $71.1 million, or $0.78 per diluted share, and adjusted income from continuing operations was $73.3 million, or $0.86 per diluted share.

Acadia Healthcare reported an 11.9% increase in revenue, reaching $651.7 million. Net income attributable to Acadia totaled $80.1 million, or $0.88 per diluted share. The company raised its financial guidance for 2022, reflecting confidence in continued growth.

Acadia Healthcare reported revenue of $616.7 million, an increase of 11.9% over the first quarter of 2021. Net income attributable to Acadia totaled $60.8 million, or $0.67 per diluted share. Adjusted income from continuing operations attributable to Acadia stockholders totaled $61.2 million, or $0.67 per diluted share.

Acadia Healthcare reported a revenue of $593.5 million for Q4 2021, a 10.7% increase in same facility revenue, and a net income of $70.3 million, or $0.77 per diluted share.

Acadia Healthcare reported a revenue of $587.6 million for Q3 2021, a 7.2% increase compared to $548.0 million in Q3 2020. Net income attributable to Acadia stockholders was $66.1 million, or $0.73 per diluted share, compared to $37.0 million, or $0.42 per diluted share, for the same period last year. The company faced challenges from Hurricane Ida and the Delta variant of COVID-19, but continued to execute on strategic initiatives, adding 104 beds and opening two new CTCs.

Acadia Healthcare reported revenue of $582.2 million for the second quarter of 2021, a significant increase from $491.5 million in the same period last year. Net income attributable to Acadia stockholders was $44.5 million, or $0.49 per diluted share, compared to $41.1 million, or $0.46 per diluted share, for the second quarter of 2020. The company is increasing financial guidance for 2021.

Acadia Healthcare reported a strong start to 2021, with revenue increasing by 8.2% to $551.2 million. The company's same facility revenue grew by 7.4%, and adjusted EBITDA was $119.5 million. Acadia is focused on strategic investments in facility expansions, de novo facilities, and joint venture partnerships to drive long-term growth.

Acadia Healthcare reported a revenue increase in Q4 2020 compared to the previous year, driven by solid volumes and strong cost management in their U.S. operations. However, the company experienced a net loss due to discontinued operations related to the sale of their U.K. business.

Acadia Healthcare reported revenue of $833.3 million for Q3 2020, compared to $777.3 million for Q3 2019. Net income attributable to Acadia stockholders for Q3 2020 was $37.0 million, or $0.42 per diluted share, compared to $42.6 million, or $0.48 per diluted share, for the same period in 2019.

Acadia Healthcare reported a decrease in revenue for Q2 2020, with $750.3 million compared to $789.4 million in Q2 2019. Net income attributable to Acadia stockholders was $41.1 million, or $0.46 per diluted share, compared to $48.1 million, or $0.55 per diluted share, for the same period in 2019.

Acadia Healthcare reported a 2.9% increase in revenue for the first quarter of 2020, reaching $782.8 million. Net income attributable to Acadia stockholders was $33.5 million, or $0.38 per diluted share. The company withdrew its full-year 2020 guidance due to COVID-19 uncertainty but remains confident in its long-term growth opportunities.

Acadia Healthcare reported Q4 2019 revenue of $780.2 million, a 4.9% increase year-over-year. The company experienced a net loss of $11.3 million, or $0.13 per diluted share. U.S. facilities showed improvement, and the company is proceeding with the sale of its U.K. business.